ĐÁNH GIÁ HIỆU QUẢ HÓA XẠ TRỊ ĐỒNG THỜI TIỀN PHẪU TRONG ĐIỀU TRỊ UNG THƯ THỰC QUẢN 1/3 GIỮA, DƯỚI GIAI ĐOẠN II, III

Abstract

Objectives: To describe some clinical and paraclinical characteristics and evaluate treatment outcomes of preoperative concurrent chemoradiotherapy for patients with stage II, III middle- lower third esophageal cancer. Subjects and methods: A descriptive retrospective combined prospective study on 32 patients with stage II, III middle- lower third esophageal cancer receiving preoperative concurrent chemoradiotherapy with weekly Paclitaxel/Carboplatin regimen (the dose of Paclitaxel was 50mg/m2 in combination with Carrboplatin administered the dose at AUC 2) and radiation with a dose of 41.4Gy/23Fr followed by surgery. Results: The means age was 55.22 ± 8.8 years old, the percentage of male was 100%. The rate of dysphagia was 87.5%, the mean length of tumor was 5.09+1.51cm. The pathology of patients was squamous cell carcinoma (100%) and most of them staged III (87.5%). After chemoradiotherapy, the overall clinical response rate reached 87.5%, the respone rate according to RECIST 1.1 criteria was 87.5% with 37.5% of the patients achieving complete response. After chemoradiotherapy, 68.8% of patients underwent surgery. The pathologic complete response (pCR) rate was 45.5% and the rate of R0 resecsion was 100%. Conclusion: Preoperative concurrent chemoradiotherapy with weekly PC regimen and radiotherapy (41.4 Gy/23Fr) is an effective treatment for patients with stage II, III middle- lower third esophageal cancer.